Actinium Pharmaceuticals Inc (ATNM)

[SV Solar Surge]

Found this posted on Ihub under another stocks news. Merck holds large position in $ATNM & possible acquisition target.

Special Profile & Four Companies Where Investors are Anticipating Success

Source: InvestorsHub NewsWire
NEW YORK, NY -- June 3, 2015 – About Small Cap Traders and Four Brief Reports
Small Cap Traders makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Special Profile* - Two Clinical Stage Products Lead the Way in a Promising Pipeline and Large

Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM), (“the company”) is a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company develops cancer drugs, primarily using its Alpha Particle Immunotherapy Technology (“APIT) platform. This patented technology combines monoclonal antibodies (mAB) for targeting specific types of cells with alpha emitting radioisotopes (actinium-225 and bismuth-213), and specific beta emitting radiopharmaceuticals, to precisely target and kill cancerous cells. The Company’s products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC).

Company Highlights

- Completed secondary offering, resulting in approximately $18.4 million in proceeds.
- Attained Orphan-Drug Status for Actimab™-A.
- Announced filing for Investigational New Drug meeting with U.S. FDA to finalize development of Iomab™-B.
- Prepared for Phase 3 Trial of Iomab™-B and Phase 2 Trial of Actimab™-A by mid-year 2015.
- Merck a leading drug manufacturer holds a large position in company. (Making ATNM a Possible Acquisition Target)
For a full analyst report on ATNM that includes a company overview, market and competition breakdown, recent events, outlook, valuation, analyst summary and recommendation can be viewed by using the following link at no cost:
http://bit.ly/--ATNM--AnalystReport